Efficacy of Benralizumab in Reducing FeNO in Severe Eosinophilic Asthma: The Role of CRSwNP
Benralizumab reduces FeNO levels and improves clinical outcomes in severe eosinophilic asthma, especially in patients with CRSwNP. Monitoring FeNO levels provides additional insights into treatment response, highlighting its potential role as a marker in specific patient subgroups.
Authors
- N Sobrino
- Juan Luis García‐Rivero (ORCID: https://orcid.org/0000-0002-6407-5832)
- Cristina Ghadban Garrido
- Beatriz Abascal-Bolado (ORCID: https://orcid.org/0000-0001-6712-9923)
Institutions
- Marqués de Valdecilla University Hospital (ES)
- Instituto de Investigación Marqués de Valdecilla (ES)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/jaa.s506835
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00